reports
- Emira Sagaama
- Thijs Berkelder
- Emira Sagaama
- Thijs Berkelder
- Thijs Berkelder
Fastned : Q3 update confirms further jump in profitability
>Stations up 16% y-o-y & operational EBITDA per station up 37% y-o-y - Electricity sold up 39% y-o-y to 35.5 GWh vs. BEV fleet (= market) up 34% y-o-y and sessions up 33% y-o-y to 1.3m and active customers up 33% y-o-y to 474kEnergy delivered per station was up 19% y-o-y to 438 MWh, with a reported utilisation rate of 11.9% (11.4% a year ago) and like-for-like up to 13.7%Revenues up 44% y-o-y to € 21.9m vs. AAOB € 22.5m) with annualised revenues per station ...
- ING Helpdesk
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Alfen: 2025 guidance unveiled
This morning, Alfen has provided initial elements from its strategy validation and cost reduction measures assessment. Based on these elements, Alfen has drawn up sluggish 2025 guidance, eyeing limited revenue growth in FY25 compared to FY24 (vs cons. at 15% with revenue estimates standing at EUR48
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Fastned: impressive gross margin in Q3
Fastned has published its Q3 2024 key metrics and reiterated FY24 guidance this morning. Q3 sales came in at EUR21.9m (+44% YoY), implying 9M revenue of EUR59.7m and an annual run-rate of EUR87.6m (vs cons. at EUR88.0m). Fastned posted a gross margin of 83% (+8ppt vs Q3 2023 at 75%, and cons. expec
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Wim Lewi
Fastned 3Q24 trading update, Gross margin shows pricing power
3Q24 trading update confirmed the trends from 1H24. Sales growth of 44.0% to EUR 21.9m is below our expectation, but gross margin came above our expectation at 82.6% to EUR 18.1m million. 1H24 GM% stood at 73%. The GM% acceleration should be a relief as competition remains fierce, but their focus on high traffic locations shows pricing power. With 326 operational stations, Fastned is on track for its outlook of 335-350 stations FY24-end. That is just below our 352 expectation. Fastned predict...
- Thomas Vranken
Onward Medical FIRST LOOK: Entering the BCI arena
Onward announced a license agreement with the French research institute CEA for exclusive rights to Clinatec's WIMAGINE BCI. Onward already collaborated with Clinatec for several years, and now brings the technology inhouse for further development. We see the move as a solid step forward given WIMAGINE's established safety profile, long-lasting signal stability and proven compatibility with Onward's ARC-IM technology. We reiterate our € 9.3 TP and Buy rating, as we look out for the anticipated F...
- Thomas Vranken
MaaT Pharma FIRST LOOK: Phase 3 patient recruitment completed
MaaT Pharma has completed recruitment of its Phase 3 ARES trial with the last patient in treatment. The company now points to January 2025 (previously mid-4Q24) for the topline results of its pivotal study, which includes day 28 GI-ORR. 1-year OS data is expected by YE25. We view the ARES readout as an important catalyst for the stock, which is already partially de-risked by the solid data from the ongoing EAP program. We reiterate our € 14 TP and Buy rating.
- Thijs Berkelder
Alfen : Preparing for weaker for longer
>Update on strategy and cost reduction measures: 15% job reduction - Alfen this morning publishes an update on its strategy and cost reduction measures, with three core decisions / points to mention:(1) Three business segments to remain: "Strategy validation confirms Alfen’s continued focus on its three product lines Smart Grid Solutions, Energy Storage Systems and EV Charging."(2) Outlook 2025: "Limited revenue growth is projected from 2024 to 2025 due to c...
- Thomas Vranken
Inventiva Tranched equity raise lifts financing overhang
Yesterday, Inventiva announced an impressive € 348m equity financing round in a multi-tranche approach to finance its ongoing Phase 3 NATiV3 trial with lead asset lanifibranor in MASH. The first tranche of € 94m extends the prior cash runway from mid-October 2024 to the end of 2Q25. Furthermore, a second tranche of € 116m shares could extend runway beyond the expected NATiV3 readout in 2H26 and support a study initiation in compensated cirrhosis. The final tranche of € 116m could be used to fund...
MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES...
LYON, France--(BUSINESS WIRE)-- Regulatory News : (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd'hui la fin du recrutement de son essai clinique de Phase 3 destiné à évaluer son candidat-médicament le plus avancé, MaaT013, pour le traitement de la maladie aiguë du greffon contre l'hôte (aGvH) réfractaire aux stéroïdes et réfractaire ou intolérante au ruxolit...
ONWARD® Medical signe un accord avec le CEA pour obtenir les droits ex...
ONWARD® Medical signe un accord avec le CEA pour obtenir les droits exclusifs de la technologie d’interface cerveau machine (BCI) WIMAGINE® de Clinatec CE COMMUNIQUÉ DE PRESSE CONTIENT DES INFORMATIONS PRIVÉES AU SENS DE L'ARTICLE (7)(1) DU RÈGLEMENT EUROPÉEN SUR LES ABUS DE MARCHÉ (596/2014) L'entreprise obtient les droits exclusifs pour intégrer l’interface cerveau machine WIMAGINE dans son système ARC-BCI™ Le WIMAGINE BCI dispose de 7 ans de données de sécurité clinique sur des patients humains Cet accord offre à ONWARD Medical l'opportunité d'être le premier sur le marché avec un sy...
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT01...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced full recruitment of its Phase 3 clinical trial designed to evaluate efficacy and safety of its lead asset MaaT013 in the treatment of steroid refractory and ruxolitinib refractory or intolerant acute Graft-versus-Host Disease (aGvHD) (). This achievement is one of the most significant milestones in th...
ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clina...
ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clinatec’s WIMAGINE® Brain-Computer Interface (BCI) Technology THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Company secures exclusive rights to incorporate the WIMAGINE BCI into its ARC-BCI™ System WIMAGINE BCI has 7-year human safety data Deal provides opportunity for ONWARD to be first-to-market with a BCI-enabled system to restore thought-driven movement after paralysis EINDHOVEN, the Netherlands, Oct. 15, 2024 (GLOBE NEWSWIRE)...
Inventiva annonce la mise à disposition d'un prospectus dans le cadre ...
Inventiva annonce la mise à disposition d'un prospectus dans le cadre de son financement par l’émission d’actions ordinaires et de bons de souscription d’action préfinancés Daix (France), Long Island City (New York, États-Unis), le 14 octobre 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d’autres maladies avec un besoin médical non satisfait...
- Thomas Vranken
Inventiva FIRST LOOK: Raising up to € 348m in multi-tranche equity fin...
Inventiva raises up to € 348m in a multi-tranche equity financing, of which € 94.1m gross proceeds upfront. The first tranche extends Inventiva's runway into 2Q25, and if all tranches are triggered, would fully support the company's Phase 3 NATiV3 trial and commercial launch for lanifibranor. With the backing of a strong international investor syndicate, the transaction thereby largely resolves IVA's financing overhang in our view.
Inventiva announces Filing of 2024 Half-Year Report – Conditions for A...
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the filing, for the six-month ...
Inventiva publie son Rapport Financier Semestriel 2024 – Modalités de ...
Inventiva publie son Rapport Financier Semestriel 2024 – Modalités de mise à disposition ou de consultation Daix (France), Long Island City (New York, États-Unis), le 14 octobre 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH » ), et d’autres maladies avec un besoin médical n...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.